MitoQ for Fatigue in Multiple Sclerosis (MS)
MitoQ for Fatigue in Multiple Sclerosis: A Placebo Controlled Trial
What it found
The main measure did not show a significant benefit.
| Measure | Estimate | 95% CI | p |
|---|---|---|---|
| Modified Fatigue Inventory Scale (MFIS) | 0.9489 |
Statistical analysis as posted on ClinicalTrials.gov.
What was tested
Treatment tested
- Mitoquinone cation
Placebo
- Placebo
Results by group
Modified Fatigue Inventory Scale (MFIS)
Week 1, Week 7, Week 13
| Group | Value | Interval | Number analysed |
|---|---|---|---|
| Placebo | 46.5 units on a scale | 2.8 (Standard Error) | 16 |
| 20mg of MitoQ | 55.2 units on a scale | 2.8 (Standard Error) | 15 |
| 40mg of MitoQ | 54.3 units on a scale | 2.9 (Standard Error) | 14 |
| Placebo | 45.1 units on a scale | 3.1 (Standard Error) | 16 |
| 20mg of MitoQ | 50.5 units on a scale | 2.9 (Standard Error) | 15 |
| 40mg of MitoQ | 49 units on a scale | 3.1 (Standard Error) | 14 |
| Placebo | 39.7 units on a scale | 2.8 (Standard Error) | 16 |
| 20mg of MitoQ | 48.7 units on a scale | 2.8 (Standard Error) | 15 |
| 40mg of MitoQ | 47.8 units on a scale | 3 (Standard Error) | 14 |
p = 0.9489
Values as posted on ClinicalTrials.gov. Outcomes measured differently across trials are not directly comparable.
Safety
| Group | Participants at risk | Serious adverse events | Deaths |
|---|---|---|---|
| Placebo | 16 | 0 (0.0%) | 0 |
| 20mg of MitoQ | 15 | 0 (0.0%) | 0 |
| 40mg of MitoQ | 14 | 0 (0.0%) | 0 |
As posted on ClinicalTrials.gov. Serious adverse events include any serious health event during the trial, whether or not the treatment caused it.
What it measured
Main measures
Modified Fatigue Inventory Scale (MFIS)
Week 1, Week 7, Week 13
Fatigue
Other measures (3)
Symbol Digit Modalities Test (SDMT)
Week 1, Week 7, Week 13
Thinking and memoryExpanded Disability Status Scale (EDSS)
12 weeks
Disability progressionBeck's Depression Inventory (BDI)
12 weeks
Mood and sleep
Who could take part
MS (type not specified) · 18 to 70 · EDSS 2 to 8
Show the full criteria
Inclusion criteria
* MS (any clinical subtype) as diagnosed by the 2017 McDonald criteria * EDSS score of 2 to 8 * complaint of fatigue that has been persistent for at least two months * Modified Fatigue Impact Scale (MFIS) score of 38 or greater
Exclusion criteria
* treatment with systemic glucocorticoids in the prior six weeks * Beck Depression Inventory (BDI) >31 or BDI-FS>10 (severe depression) * significant MS exacerbation in prior 30 days * previous use of MitoQ or Coenzyme Q10 (CoQ10) within thirty days of screening appointment * other significant health problem that might increase risk of patient experiencing Adverse Events (AEs), e.g.: * active coronary heart disease * liver disease * pulmonary disease * diabetes mellitus * pregnancy or intending to become pregnant or breastfeeding * unable to complete the self-report forms * unable to give informed consent * prisoners * any condition which would make the patient in the opinion of the investigator unsuitable for the study
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The purpose of this study is to determine whether MS patients who receive Oral mitoquinone (MitoQ) have less fatigue than those receiving a placebo. A comparison between patient's fatigue scored at baseline and fatigue scored 12 weeks after drug initiation will assess if MitoQ has a significant change in fatigue.
Papers
Loading reviews and guidelines…
History
Started
Apr 2020
Main results due
Oct 2024
Finished
Mar 2026
Results posted
Oct 2025